18 April 2017 - Early data suggests Tecentriq shows strong efficacy for metastatic bladder cancer patients, offering the first new treatment option in more than 30 years.

Roche Canada announced today that Health Canada has approved with conditions Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

• Have disease progression during or following platinum-containing chemotherapy
  
• Have disease progression within 12 months of neo-adjuvant (before surgery) or adjuvant (after surgery) treatment with platinum-containing chemotherapy
  

Read Roche Canada press release